Bernd R. Seizinger net worth and biography

Bernd Seizinger Biography and Net Worth

Director of Oncolytics Biotech

Dr. Bernd Seizinger currently serves as chairman/board member in a number of public and private biotech companies in the U.S., Europe and Canada, including: Vaccibody, Oxford BioTherapeutics, Aprea, CryptoMedix, and BioInvent. Previously he was President & CEO of public oncology company GPC Biotech; VP Oncology Drug Discovery and – in parallel – VP Corporate and Academic Alliances at Bristol-Myers Squibb; and Executive VP and CSO, Genome Therapeutics. Prior to his corporate appointments, he held Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.

What is Bernd R. Seizinger's net worth?: The estimated net worth of Bernd R. Seizinger is at least $451.42 thousand as of February 11th, 2026. Dr. Seizinger owns 526,991 shares of Oncolytics Biotech stock worth more than $451,420 as of August 28th. This net worth approximation does not reflect any other investments that Dr. Seizinger may own. Learn More about Bernd R. Seizinger's net worth.
How do I contact Bernd R. Seizinger?: The corporate mailing address for Dr. Seizinger and other Oncolytics Biotech executives is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. Oncolytics Biotech can also be reached via phone at (403) 670-7377 and via email at [email protected]. Learn More on Bernd R. Seizinger's contact information.
Has Bernd R. Seizinger been buying or selling shares of Oncolytics Biotech?: Bernd R. Seizinger has not been actively trading shares of Oncolytics Biotech during the last quarter. Most recently, on Thursday, February 12th, Bernd R. Seizinger bought 40,000 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $34,000.00. Following the completion of the transaction, the director now directly owns 566,991 shares of the company's stock, valued at $481,942.35. Learn More on Bernd R. Seizinger's trading history.
Who are Oncolytics Biotech's active insiders?: Oncolytics Biotech's insider roster includes Andrew Aromando (Chief Business Officer), Allison Hagerman (Chief Technology Officer), and Bernd Seizinger (Director). Learn More on Oncolytics Biotech's active insiders.
Are insiders buying or selling shares of Oncolytics Biotech?: During the last year, Oncolytics Biotech insiders bought shares 14 times. They purchased a total of 404,282 shares worth more than $363,231.56. The most recent insider tranaction occured on March, 12th when CEO Jared Kelly bought 5,050 shares worth more than $4,848.00. Insiders at Oncolytics Biotech own 0.1% of the company. Learn More about insider trades at Oncolytics Biotech.
Information on this page was last updated on 3/12/2026.

Bernd R. Seizinger Insider Trading History at Oncolytics Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/12/2026	Buy	40,000	$0.85	$34,000.00	566,991
2/11/2026	Buy	60,000	$0.83	$49,800.00	526,991
1/16/2026	Buy	100,000	$1.04	$104,000.00	466,991

Bernd R. Seizinger Buying and Selling Activity at Oncolytics Biotech

Oncolytics Biotech Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: $0.86

$0.82

$0.86

50 Day Range

MA: $0.85

$0.75

$0.96

2 Week Range

Now: $0.86

$0.73

$1.51

Volume

671,581 shs

Average Volume

1,275,658 shs

Market Capitalization

$109.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13